Dr. Novack published the lead article in the June 2024 issue of the American Journal of Ophthalmology. In this article, he showed a time line of key U.S. FDA registration and the availability of ocular hypotensive drugs (i.e., drugs that decrease elevated intraocular pressure) to patients and their doctors. He concludes that “Concomitant with public health events, the laws that the US Congress enacted in response to these events, as well as increasing scientific standards have been increased magnitude and quality of the
clinical data used to support the these now sterile, stable, safe, and effective drug products into our therapeutic pharmacopeia, while providing rapid review of NDAs.
